Company intelligence / Profile preview

TECHTRA

Kalamazoo, Michigan, USAtechtra.hu ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Tetra has completed Phase 2 clinical trials of its lead drug candidate, BPN‑14770, showing evidence of slowing progression in early Alzheimer’s disease and benefit in Fragile X syndrome. A Phase 3 trial for Fragile X syndrome is underway with results expected late 2024. The company was acquired by Shionogi after promising early results.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

NIH Blueprint Neurotherapeutics Network/NIH grantsStrategic alliance and acquisition by Shionogi & Co., Ltd.

Beyond the preview

Go deeper on TECHTRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TECHTRA.

Explore the full profile